Novo Nordisk’s Bold Gambit to Reclaim US Market Dominance
Published on 11/22/2025 at 05:05 | Redaktion boerse-global.de
Facing intense competitive pressure, Danish pharmaceutical leader Novo Nordisk is executing a dramatic strategic pivot. With its shares down more than 51% since the start of the year, management is deploying aggressive tactics to defend its crucial US market position against rival Eli Lilly. The company’s latest moves signal a fundamental shift from premium pricing to volume-driven market share defense.
In a significant departure from conventional distribution models, Novo Nordisk will begin selling its blockbuster weight-loss medication Wegovy directly to employers starting January 1. This strategic maneuver effectively circumvents the powerful intermediary Pharmacy Benefit Managers (PBMs) that typically control drug distribution in the United States.
The company has partnered with Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
